Aura Biosciences Inc.

NASDAQ: AURA · Real-Time Price · USD
6.16
0.09 (1.48%)
At close: May 02, 2025, 3:59 PM
6.15
-0.16%
After-hours: May 02, 2025, 04:05 PM EDT
1.48%
Bid 6.11
Market Cap 309.66M
Revenue (ttm) n/a
Net Income (ttm) -86.92M
EPS (ttm) -1.75
PE Ratio (ttm) -3.52
Forward PE -2.62
Analyst Strong Buy
Ask 6.18
Volume 90,837
Avg. Volume (20D) 262,758
Open 6.19
Previous Close 6.07
Day's Range 6.13 - 6.28
52-Week Range 4.84 - 12.38
Beta 0.43

About AURA

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was inc...

Industry Biotechnology
Sector Healthcare
IPO Date Oct 29, 2021
Employees 106
Stock Exchange NASDAQ
Ticker Symbol AURA
Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for AURA stock is "Strong Buy." The 12-month stock price forecast is $23.5, which is an increase of 281.49% from the latest price.

Stock Forecasts
6 months ago
+14.09%
Aura Biosciences shares are trading higher after H... Unlock content with Pro Subscription
6 months ago
+0.39%
Aura Biosciences shares are trading higher after the company announced multiple complete clinical responses following its single low-dose administration of Bel-sar in patients with non-muscle-invasive bladder cancer in its ongoing Phase 1 trial.